LEADER Trial Eligibility and Preventable Cardiovascular Events in US Adults with Diabetes: the National Health and Nutrition Examination Surveys 2007-2016.

Wenjun FanCorey TongNathan D Wong

Published in: Cardiovascular drugs and therapy (2020)

Liraglutide may prevent many fatal and non-fatal CVD events if provided to US adults meeting LEADER eligibility criteria. More efforts are needed to educate the healthcare providers on the CVD benefits from newer diabetes therapies, including liraglutide.

Keyphrases

cardiovascular events
cardiovascular disease
type diabetes
healthcare
coronary artery disease
glycemic control
clinical trial
physical activity
study protocol
phase iii
emergency department
adipose tissue
adverse drug
skeletal muscle
social media
double blind